Danziger Asaf
SEC CIK 1654435 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | Dir | 416.7K | $509.5K | $23.11M | 12 | 2021-07-06 | 2026-06-30 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
| 18 | Danziger Asaf | Dir | — | — |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 16:30 | 2026-06-30 | NVCR | NovoCure Ltd | Danziger Asaf | Dir | A - Grant | $11.15 | +268 | 416.7K | +0.1% | +$2,988 | |
| 2025-07-01 | 2025-06-30 | NVCR | NovoCure Ltd | Danziger Asaf | Dir | A - Grant | $15.13 | +833 | 416.5K | +0.2% | +$12.6K | |
| M | 2025-01-03 | 2024-12-31+ | NVCR | NovoCure Ltd | Danziger Asaf | Dir | A - Grant | $0.0152 | +400.4K | 15.6K | New | +$6,077 |
| 2024-08-06 | 2024-06-28 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $12.24 | +1,239 | 15.2K | +9% | +$15.2K | |
| 2023-07-06 | 2023-06-30 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $35.28 | +367 | 14.0K | +3% | +$12.9K | |
| D | 2023-01-09 | 2023-01-06 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $62.31 | +39 | 13.6K | +0.3% | +$2,430 |
| DM | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | S - Sale+OE | $108.73 | -212.5K | 15.4K | -93% | -$23.11M |
| DM | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | M - OptEx | $7.66 | +212.5K | 38.6K | New | +$1.63M |
| 2022-07-07 | 2022-07-05 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $59.08 | +276 | 13.6K | +2% | +$16.3K | |
| 2022-01-12 | 2022-01-06 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $63.82 | +31 | 13.3K | +0.2% | +$1,978 | |
| M | 2021-11-29 | 2021-11-26 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | P - Purchase | $102.44 | +4,974 | 13.3K | +60% | +$509.5K |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Danziger Asaf | CEO, Dir | A - Grant | $137.12 | +118 | 8,302 | +1% | +$16.2K |
Purchase Sale Sale after option exercise All abbreviations